HHS awards $7.2M contract to Battelle for sulfur mustard inhalation injury research, focusing on medical countermeasures

Contract Overview

Contract Amount: $7,245,351 ($7.2M)

Contractor: Battelle Memorial Institute

Awarding Agency: Department of Health and Human Services

Start Date: 2025-09-29

End Date: 2027-03-28

Contract Duration: 545 days

Daily Burn Rate: $13.3K/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: COST PLUS FIXED FEE

Sector: R&D

Official Description: USE OF A HUMAN-RELEVANT SMALL ANIMAL MODEL OF SULFUR MUSTARD (SM)-INDUCED INHALATION INJURIES TO SCREEN POTENTIAL MEDICAL COUNTERMEASURES (MCMS)

Place of Performance

Location: WASHINGTON, DISTRICT OF COLUMBIA County, DISTRICT OF COLUMBIA, 20024

State: District of Columbia Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $7.2 million to BATTELLE MEMORIAL INSTITUTE for work described as: USE OF A HUMAN-RELEVANT SMALL ANIMAL MODEL OF SULFUR MUSTARD (SM)-INDUCED INHALATION INJURIES TO SCREEN POTENTIAL MEDICAL COUNTERMEASURES (MCMS) Key points: 1. Contract awarded via full and open competition, suggesting a competitive bidding process. 2. Research and Development in Biotechnology sector, focusing on a critical area of public health preparedness. 3. Contract duration of 545 days indicates a focused, project-based research effort. 4. The use of a small animal model suggests a controlled, preclinical approach to testing. 5. The contract type is Cost Plus Fixed Fee, which allows for flexibility in research costs while providing a defined fee for the contractor. 6. This award contributes to the broader effort of developing medical countermeasures for chemical warfare agents.

Value Assessment

Rating: good

The contract value of $7.2 million for a 545-day research project in biotechnology appears reasonable given the specialized nature of the work. Benchmarking against similar R&D contracts for developing medical countermeasures against chemical agents would provide a more precise assessment, but the scope suggests a significant research undertaking. The Cost Plus Fixed Fee structure is common for R&D where exact costs can be uncertain, balancing contractor incentive with cost control.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple bidders had the opportunity to submit proposals. This method is generally preferred as it fosters a competitive environment, potentially leading to better pricing and innovative solutions. The number of bidders is not specified, but the open competition suggests a robust selection process.

Taxpayer Impact: Taxpayers benefit from full and open competition through potentially lower prices and a wider array of technical approaches being considered, ensuring the government receives the best value for its investment.

Public Impact

The primary beneficiaries are public health and national security, through the development of potential treatments for sulfur mustard exposure. The services delivered involve advanced biomedical research, specifically the screening of medical countermeasures using a relevant animal model. The geographic impact is primarily national, contributing to the U.S. government's preparedness capabilities. Workforce implications include employment for specialized researchers, scientists, and technicians within the biotechnology and R&D sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for cost overruns inherent in Cost Plus Fixed Fee contracts if not closely monitored.
Reliance on animal models may not perfectly translate to human efficacy, requiring further validation.
The specialized nature of the research could limit the pool of qualified contractors, despite open competition.

Positive Signals

Awarded through full and open competition, suggesting a competitive and potentially cost-effective process.
Focus on a critical public health threat (sulfur mustard) aligns with national security and preparedness goals.
The use of a specific, relevant animal model indicates a targeted and scientifically grounded research approach.

Sector Analysis

This contract falls within the Biotechnology Research and Development sector, a critical area for national security and public health preparedness. The market for developing medical countermeasures against chemical and biological threats is specialized, often involving government funding and a limited number of highly capable research institutions and companies. Spending in this sector is driven by evolving threats and the need for advanced medical solutions, with contracts often being long-term and complex.

Small Business Impact

The contract does not indicate any specific small business set-aside. Given the specialized nature of biotechnology R&D, particularly in developing countermeasures for chemical agents, the prime contractor, Battelle Memorial Institute, is a large research organization. There may be opportunities for small businesses to participate as subcontractors, but this is not explicitly detailed in the award information.

Oversight & Accountability

Oversight for this contract will likely be managed by the Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS. Mechanisms would include regular progress reports, financial reviews, and adherence to research protocols. Transparency is generally maintained through contract award databases and public reporting of research outcomes, though specific research data may be sensitive. Inspector General jurisdiction would apply to any allegations of fraud, waste, or abuse.

Related Government Programs

Medical Countermeasures (MCM) Development Programs
Chemical and Biological Defense Research
Biotechnology Research Grants
National Biodefense Strategy Initiatives

Risk Flags

Cost Plus Fixed Fee contract type requires careful monitoring to manage potential cost overruns.
Reliance on animal models necessitates validation for human efficacy.
Specialized research area may limit the number of qualified bidders despite open competition.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $7.2 million to BATTELLE MEMORIAL INSTITUTE. USE OF A HUMAN-RELEVANT SMALL ANIMAL MODEL OF SULFUR MUSTARD (SM)-INDUCED INHALATION INJURIES TO SCREEN POTENTIAL MEDICAL COUNTERMEASURES (MCMS)

Who is the contractor on this award?

The obligated recipient is BATTELLE MEMORIAL INSTITUTE.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Office of Assistant Secretary for Preparedness and Response).

What is the total obligated amount?

The obligated amount is $7.2 million.

What is the period of performance?

Start: 2025-09-29. End: 2027-03-28.

What is Battelle Memorial Institute's track record in similar R&D contracts for the Department of Health and Human Services or other defense-related agencies?

Battelle Memorial Institute has a significant track record in research and development across various scientific and engineering disciplines, including significant work for government agencies like HHS and the Department of Defense. They have experience in areas relevant to chemical and biological defense, including the development and testing of medical countermeasures. Their portfolio often includes complex R&D projects requiring specialized facilities and expertise. A detailed review of their past performance on similar cost-plus-fixed-fee contracts, particularly those involving animal modeling for toxic exposures, would be necessary to fully assess their suitability and past success rates in delivering on similar objectives and managing project costs effectively.

How does the $7.2 million contract value compare to other federal investments in sulfur mustard countermeasure research?

The $7.2 million contract value for this specific project represents a focused investment in screening potential medical countermeasures using a small animal model. Federal spending on sulfur mustard countermeasures is part of a broader chemical and biological defense R&D portfolio, which can encompass basic research, preclinical studies, clinical trials, and manufacturing scale-up. While $7.2 million is a substantial amount for a single research contract of this duration (545 days), it is likely one component of a larger, multi-year federal strategy. Benchmarking requires comparing it to the total federal investment in this specific threat area, considering the varying stages of research and development across different contracts and agencies. Without a broader analysis of the entire R&D landscape for sulfur mustard, it's difficult to definitively state if this specific award is high or low relative to the overall federal effort.

What are the primary risks associated with this specific research contract, beyond general R&D uncertainties?

Beyond the inherent risks in any R&D project, specific risks for this contract include the efficacy and translatability of the small animal model to human responses to sulfur mustard inhalation. There's also the risk that none of the screened countermeasures prove effective, leading to a need for further research or alternative approaches. Operational risks could involve challenges in maintaining the animal model, ensuring safety protocols for handling toxic agents, and managing the complexities of a Cost Plus Fixed Fee contract to prevent cost overruns. Furthermore, the long-term availability of funding for subsequent research phases, should initial screening be successful, could pose a programmatic risk.

How effective is the use of small animal models in screening medical countermeasures for chemical warfare agents like sulfur mustard?

Small animal models, such as rodents, are widely used in the initial screening of medical countermeasures (MCMs) for chemical warfare agents due to ethical considerations, cost-effectiveness, and the ability to control variables. These models can mimic certain aspects of human exposure and physiological responses, allowing researchers to assess the potential efficacy of candidate MCMs in a controlled environment. However, they have limitations. Species differences can affect how the agent and the MCM are metabolized and affect the body, meaning results from animal models do not always perfectly predict human outcomes. Despite these limitations, they are a crucial first step in the MCM development pipeline, helping to identify promising candidates for further, more complex testing, including in larger animal models and eventually human clinical trials.

What is the historical spending pattern for research and development in biotechnology (except Nanobiotechnology) by the Office of Assistant Secretary for Preparedness and Response (ASPR)?

The Office of Assistant Secretary for Preparedness and Response (ASPR) within HHS is specifically tasked with preparing the nation for the health effects of public health emergencies, including those caused by chemical, biological, radiological, and nuclear threats. Consequently, ASPR's spending in the 'Research and Development in Biotechnology (except Nanobiotechnology)' category is likely to be substantial and focused on developing medical countermeasures. Historical spending patterns would reflect priorities in threat assessment and preparedness. This includes investments in areas like vaccine development, therapeutics, and diagnostics for emerging infectious diseases and deliberate threats. Analyzing ASPR's budget justifications and contract databases over several fiscal years would reveal trends in funding allocation towards specific research areas and technologies within biotechnology R&D, showing a consistent commitment to advancing MCM capabilities.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in Biotechnology (except Nanobiotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: COST PLUS FIXED FEE (U)

Evaluated Preference: NONE

Contractor Details

Address: 505 KING AVE, COLUMBUS, OH, 43201

Business Categories: Category Business, Corporate Entity Tax Exempt, Manufacturer of Goods, Nonprofit Organization, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $18,211,716

Exercised Options: $7,245,351

Current Obligation: $7,245,351

Actual Outlays: $216,115

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 75A50122D00007

IDV Type: IDC

Timeline